{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:34Z","timestamp":1790806834699,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Retinopathy of prematurity (ROP) is a vasoproliferative disorder of the premature retina with the potential to progress to extraretinal neovascularisation. This review serves as an introduction to retinopathy of prematurity (ROP), outlining key parts of ROP pathophysiology, diagnosis and treatment. ROP is traditionally diagnosed by indirect ophthalmoscopy and classified using anatomical zones, stages of disease, and the presence or absence of \u201cplus disease\u201d (dilation and tortuosity of the major retinal arterioles and venules). ROP has a bi-phasic pathophysiology: initial hyperoxia causes reduced retinal vascularisation, followed by pathological vaso-proliferation resulting from subsequent hypoxia and driven by vascular endothelial growth factor (VEGF).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Advancements in management<\/jats:title>\n                <jats:p>This review summarises previous trials to establish optimum oxygen exposure levels in newborns and more recently the development of anti-VEGF agents locally delivered to block pathological neovascularisation, which is technically easier to administer and less destructive than laser treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Future directions<\/jats:title>\n                <jats:p>There remains an ongoing concern regarding the potential unwanted systemic effects of intravitreally administered anti-VEGF on the overall development of the premature baby. Ongoing dosing studies may lessen these fears by identifying the minimally effective dose required to block extraretinal neovascularisation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40348-023-00163-5","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T07:14:37Z","timestamp":1694762077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Retinopathy of prematurity: from oxygen management to molecular manipulation"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6179-6714","authenticated-orcid":false,"given":"Jonathan","family":"Woods","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmito","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"issue":"9832","key":"163_CR1","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(12)60820-4","volume":"379","author":"H Blencowe","year":"2012","unstructured":"Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R et al (2012) National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 379(9832):2162\u20132172. https:\/\/doi.org\/10.1016\/S0140-6736(12)60820-4","journal-title":"Lancet"},{"issue":"10063","key":"163_CR2","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1016\/S0140-6736(16)31593-8","volume":"388","author":"L Liu","year":"2016","unstructured":"Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J et al (2016) Global, regional, and national causes of under-5 mortality in 2000\u201315: an updated systematic analysis with implications for the sustainable development goals. Lancet 388(10063):3027\u20133035. https:\/\/doi.org\/10.1016\/S0140-6736(16)31593-8","journal-title":"Lancet"},{"issue":"5","key":"163_CR3","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1542\/peds.2004-1180","volume":"115","author":"C Gilbert","year":"2005","unstructured":"Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P et al (2005) Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 115(5):e518\u2013e525. https:\/\/doi.org\/10.1542\/peds.2004-1180","journal-title":"Pediatrics"},{"issue":"3","key":"163_CR4","doi-asserted-by":"publisher","first-page":"e013366","DOI":"10.1136\/bmjopen-2016-013366","volume":"7","author":"G Adams","year":"2017","unstructured":"Adams G, Bunce C, Xing W, Butler L, Long V, Reddy A et al (2017) Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk. BMJ Open 7(3):e013366. https:\/\/doi.org\/10.1136\/bmjopen-2016-013366","journal-title":"BMJ Open"},{"issue":"4","key":"163_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5693\/djo.01.2019.08.002","volume":"25","author":"T Bowe","year":"2019","unstructured":"Bowe T, Nyamai L, Ademola-Popoola D, Amphornphruet A, Anzures R, Cernichiaro-Espinosa LA et al (2019) The current state of retinopathy of prematurity in India, Kenya, Mexico, Nigeria, Philippines, Romania, Thailand, and Venezuela. Digit J Ophthalmol 25(4):49\u201358. https:\/\/doi.org\/10.5693\/djo.01.2019.08.002","journal-title":"Digit J Ophthalmol"},{"key":"163_CR6","first-page":"554","volume-title":"Larsen\u2019s human embryology","author":"GC Schoenwolf","year":"2015","unstructured":"Schoenwolf GC, Bleyl SB, Brauer PR, Francis-West PH (2015) Larsen\u2019s human embryology, 5th edn. Churchill Livingstone, Philadelphia, p 554","edition":"5"},{"issue":"4","key":"163_CR7","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/0002-9378(89)90770-9","volume":"161","author":"KH Nicolaides","year":"1989","unstructured":"Nicolaides KH, Economides DL, Soothill PW (1989) Blood gases, pH, and lactate in appropriate- and small-for-gestational-age fetuses. Am J Obstet Gynecol 161(4):996\u20131001. https:\/\/doi.org\/10.1016\/0002-9378(89)90770-9","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"163_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/archopht.1952.00920010086012","volume":"48","author":"VM Crosse","year":"1952","unstructured":"Crosse VM, Evans PJ (1952) Prevention of retrolental fibroplasia. Arch Ophthalmol 48(1):83\u201387. https:\/\/doi.org\/10.1001\/archopht.1952.00920010086012","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"163_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000308454","volume":"99","author":"AK Hauspurg","year":"2011","unstructured":"Hauspurg AK, Allred EN, Vanderveen DK, Chen M, Bednarek FJ, Cole C et al (2011) Blood gases and retinopathy of prematurity: the ELGAN study. Neonatology 99(2):104\u2013111. https:\/\/doi.org\/10.1159\/000308454","journal-title":"Neonatology"},{"issue":"3","key":"163_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.pedneo.2016.03.009","volume":"58","author":"YC Wang","year":"2017","unstructured":"Wang YC, Chan OW, Chiang MC, Yang PH, Chu SM, Hsu JF et al (2017) Red blood cell transfusion and clinical outcomes in extremely low birth weight preterm infants. Pediatr Neonatol 58(3):216\u2013222. https:\/\/doi.org\/10.1016\/j.pedneo.2016.03.009","journal-title":"Pediatr Neonatol"},{"issue":"8174","key":"163_CR11","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/s0140-6736(80)90836-3","volume":"1","author":"DW Milligan","year":"1980","unstructured":"Milligan DW (1980) Failure of autoregulation and intraventricular haemorrhage in preterm infants. Lancet 1(8174):896\u2013898. https:\/\/doi.org\/10.1016\/s0140-6736(80)90836-3","journal-title":"Lancet"},{"issue":"7","key":"163_CR12","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nm1591","volume":"13","author":"KM Connor","year":"2007","unstructured":"Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A et al (2007) Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 13(7):868\u2013873. https:\/\/doi.org\/10.1038\/nm1591","journal-title":"Nat Med"},{"issue":"1","key":"163_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev.nutr.012809.104742","volume":"30","author":"P Haggarty","year":"2010","unstructured":"Haggarty P (2010) Fatty acid supply to the human fetus. Annu Rev Nutr 30(1):237\u2013255. https:\/\/doi.org\/10.1146\/annurev.nutr.012809.104742","journal-title":"Annu Rev Nutr"},{"issue":"17","key":"163_CR14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2174\/1381612824666180601094849","volume":"24","author":"N Khalesi","year":"2018","unstructured":"Khalesi N, Bordbar A, Khosravi N, Kabirian M, Karimi A (2018) The efficacy of omega-3 supplement on prevention of retinopathy of prematurity in premature infants: a randomized double-blinded controlled trial. Curr Pharm Des 24(17):1845\u20131848. https:\/\/doi.org\/10.2174\/1381612824666180601094849","journal-title":"Curr Pharm Des"},{"issue":"7","key":"163_CR15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/jpen.1497","volume":"43","author":"M Bernabe-Garc\u00eda","year":"2019","unstructured":"Bernabe-Garc\u00eda M, Villegas-Silva R, Villavicencio-Torres A, Calder PC, Rodr\u00edguez-Cruz M, Maldonado-Hern\u00e1ndez J et al (2019) Enteral docosahexaenoic acid and retinopathy of prematurity: a randomized clinical trial. J Parenter Enteral Nutr 43(7):874\u2013882. https:\/\/doi.org\/10.1002\/jpen.1497","journal-title":"J Parenter Enteral Nutr"},{"issue":"4","key":"163_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamapediatrics.2020.5653","volume":"175","author":"A Hellstr\u00f6m","year":"2021","unstructured":"Hellstr\u00f6m A, Nilsson AK, Wackernagel D, Pivodic A, Vanpee M, Sj\u00f6bom U et al (2021) Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 175(4):359\u2013367. https:\/\/doi.org\/10.1001\/jamapediatrics.2020.5653","journal-title":"JAMA Pediatr"},{"issue":"1","key":"163_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0378-3782(86)90096-4","volume":"13","author":"JD Lineham","year":"1986","unstructured":"Lineham JD, Smith RM, Dahlenburg GW, King RA, Haslam RR, Stuart MC et al (1986) Circulating insulin-like growth factor I levels in newborn premature and full-term infants followed longitudinally. Early Hum Dev 13(1):37\u201346. https:\/\/doi.org\/10.1016\/0378-3782(86)90096-4","journal-title":"Early Hum Dev"},{"issue":"10","key":"163_CR18","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1073\/pnas.101113998","volume":"98","author":"A Hellstr\u00f6m","year":"2001","unstructured":"Hellstr\u00f6m A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL et al (2001) Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 98(10):5804\u20135808. https:\/\/doi.org\/10.1073\/pnas.101113998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1\u20131","key":"163_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/pr.2015.181","volume":"79","author":"G Hellgren","year":"2016","unstructured":"Hellgren G, L\u00f6fqvist C, H\u00e5rd AL, Hansen-Pupp I, Gram M, Ley D et al (2016) Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity. Pediatr Res 79(1\u20131):70\u201375. https:\/\/doi.org\/10.1038\/pr.2015.181","journal-title":"Pediatr Res"},{"key":"163_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jpeds.2018.10.033","volume":"206","author":"D Ley","year":"2019","unstructured":"Ley D, Hallberg B, Hansen-Pupp I, Dani C, Ramenghi LA, Marlow N et al (2019) rhIGF-1\/rhIGFBP-3 in preterm infants: a phase 2 randomized controlled trial. J Pediatr 206:56\u201365.e8. https:\/\/doi.org\/10.1016\/j.jpeds.2018.10.033","journal-title":"J Pediatr"},{"issue":"3","key":"163_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/MCO.0b013e328351c472","volume":"15","author":"A Larnkj\u00e6r","year":"2012","unstructured":"Larnkj\u00e6r A, M\u00f8lgaard C, Michaelsen KF (2012) Early nutrition impact on the insulin-like growth factor axis and later health consequences. Curr Opin Clin Nutr Metab Care 15(3):285\u2013292. https:\/\/doi.org\/10.1097\/MCO.0b013e328351c472","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"1","key":"163_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.siny.2011.08.007","volume":"17","author":"J Lee","year":"2012","unstructured":"Lee J, Dammann O (2012) Perinatal infection, inflammation, and retinopathy of prematurity. Semin Fetal Neonatal Med 17(1):26\u201329. https:\/\/doi.org\/10.1016\/j.siny.2011.08.007","journal-title":"Semin Fetal Neonatal Med"},{"issue":"1","key":"163_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jpeds.2012.12.038","volume":"163","author":"SM Husain","year":"2013","unstructured":"Husain SM, Sinha AK, Bunce C, Arora P, Lopez W, Mun KS et al (2013) Relationships between maternal ethnicity, gestational age, birth weight, weight gain, and severe retinopathy of prematurity. J Pediatr 163(1):67\u201372. https:\/\/doi.org\/10.1016\/j.jpeds.2012.12.038","journal-title":"J Pediatr"},{"issue":"9902","key":"163_CR24","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstr\u00f6m","year":"2013","unstructured":"Hellstr\u00f6m A, Smith LE, Dammann O (2013) Retinopathy of prematurity. Lancet 382(9902):1445\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(13)60178-6","journal-title":"Lancet"},{"issue":"50","key":"163_CR25","doi-asserted-by":"publisher","first-page":"19898","DOI":"10.1073\/pnas.0805817105","volume":"105","author":"JE Sears","year":"2008","unstructured":"Sears JE, Hoppe G, Ebrahem Q, Anand-Apte B (2008) Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy. Proc Natl Acad Sci USA 105(50):19898\u201319903. https:\/\/doi.org\/10.1073\/pnas.0805817105","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"163_CR26","doi-asserted-by":"publisher","first-page":"F371","DOI":"10.1136\/fetalneonatal-2011-301121","volume":"97","author":"PK Shah","year":"2012","unstructured":"Shah PK, Narendran V, Kalpana N (2012) Aggressive posterior retinopathy of prematurity in large preterm babies in South India. Arch Dis Child Fetal Neonatal Ed 97(5):F371\u2013375. https:\/\/doi.org\/10.1136\/fetalneonatal-2011-301121","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"3","key":"163_CR27","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1158\/1535-7163.MCT-11-0555","volume":"11","author":"N Rahimi","year":"2012","unstructured":"Rahimi N (2012) The ubiquitin-proteasome system meets angiogenesis. Mol Cancer Ther 11(3):538\u2013548. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0555","journal-title":"Mol Cancer Ther"},{"key":"163_CR28","doi-asserted-by":"crossref","unstructured":"Hoppe G, Yoon S, Gopalan B, Savage AR, Brown R, Case K, et al (2016) Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity. Proc Natl Acad Sci 113(18):E2516\u201325. Available from: https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1523005113.\u00a0 [cited 21 June 2023]","DOI":"10.1073\/pnas.1523005113"},{"issue":"12","key":"163_CR29","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2(12):1097\u20131105. https:\/\/doi.org\/10.1177\/1947601911423031","journal-title":"Genes Cancer"},{"issue":"12","key":"163_CR30","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/70963","volume":"5","author":"LE Smith","year":"1999","unstructured":"Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X et al (1999) Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 5(12):1390\u20131395. https:\/\/doi.org\/10.1038\/70963","journal-title":"Nat Med"},{"issue":"5","key":"163_CR31","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1542\/peds.112.5.1016","volume":"112","author":"A Hellstr\u00f6m","year":"2003","unstructured":"Hellstr\u00f6m A, Engstr\u00f6m E, H\u00e5rd AL, Albertsson-Wikland K, Carlsson B, Niklasson A et al (2003) Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 112(5):1016\u20131020. https:\/\/doi.org\/10.1542\/peds.112.5.1016","journal-title":"Pediatrics"},{"issue":"9","key":"163_CR32","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.ophtha.2008.12.023","volume":"116","author":"T Sato","year":"2009","unstructured":"Sato T, Kusaka S, Shimojo H, Fujikado T (2009) Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 116(9):1599\u20131603. https:\/\/doi.org\/10.1016\/j.ophtha.2008.12.023","journal-title":"Ophthalmology"},{"issue":"11","key":"163_CR33","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/s0161-6420(91)32074-8","volume":"98","author":"EA Palmer","year":"1991","unstructured":"Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB et al (1991) Incidence and early course of retinopathy of prematurity. The cryotherapy for retinopathy of prematurity cooperative group. Ophthalmology 98(11):1628\u201340. https:\/\/doi.org\/10.1016\/s0161-6420(91)32074-8","journal-title":"Ophthalmology"},{"issue":"2","key":"163_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/archophthalmol.2010.346","volume":"129","author":"D Austeng","year":"2011","unstructured":"Austeng D, K\u00e4llen KBM, Hellstr\u00f6m A, Jakobsson PG, Johansson K, Tornqvist K et al (2011) Screening for retinopathy of prematurity in infants born before 27 weeks\u2019 gestation in Sweden. Arch Ophthalmol 129(2):167\u2013172. https:\/\/doi.org\/10.1001\/archophthalmol.2010.346","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"163_CR35","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamaophthalmol.2015.0460","volume":"133","author":"E Daniel","year":"2015","unstructured":"Daniel E, Quinn GE, Hildebrand PL, Ells A, Hubbard GB, Capone A et al (2015) Validated system for centralized grading of retinopathy of prematurity: telemedicine approaches to evaluating acute-phase retinopathy of prematurity (e-ROP) study. JAMA Ophthalmol 133(6):675\u2013682. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.0460","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"163_CR36","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","volume":"128","author":"MF Chiang","year":"2021","unstructured":"Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Paul Chan RV, Berrocal A et al (2021) International classification of retinopathy of prematurity, third edition. Ophthalmology 128(10):e51\u201368. https:\/\/doi.org\/10.1016\/j.ophtha.2021.05.031","journal-title":"Ophthalmology"},{"issue":"7","key":"163_CR37","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/j.ophtha.2022.02.008","volume":"129","author":"JP Campbell","year":"2022","unstructured":"Campbell JP, Chiang MF, Chen JS, Moshfeghi DM, Nudleman E, Ruambivoonsuk P et al (2022) Artificial intelligence for retinopathy of prematurity: validation of a vascular severity scale against international expert diagnosis. Ophthalmology 129(7):e69\u201376. https:\/\/doi.org\/10.1016\/j.ophtha.2022.02.008","journal-title":"Ophthalmology"},{"issue":"10","key":"163_CR38","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/eye.2011.170","volume":"25","author":"LC Zepeda-Romero","year":"2011","unstructured":"Zepeda-Romero LC, Martinez-Perez ME, Ruiz-Velasco S, Ramirez-Ortiz MA, Gutierrez-Padilla JA (2011) Temporary morphological changes in plus disease induced during contact digital imaging. Eye 25(10):1337\u20131340. https:\/\/doi.org\/10.1038\/eye.2011.170","journal-title":"Eye"},{"key":"163_CR39","unstructured":"Royal College of Paediatrics and Child Health (2022) UK Screening of retinopathy of prematuirty guideline. Available from: https:\/\/www.rcpch.ac.uk\/sites\/default\/files\/2022-12\/FC61116_Retinopathy_Guidelines_14.12.22.pdf [cited 28 June 2023]"},{"issue":"2","key":"163_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1542\/peds.105.2.295","volume":"105","author":"The STOP-ROP Multicenter Study Group","year":"2000","unstructured":"The STOP-ROP Multicenter Study Group (2000) Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP): a randomized, controlled trial. I: primary outcomes. Pediatrics 105(2):295\u2013310. https:\/\/doi.org\/10.1542\/peds.105.2.295","journal-title":"Pediatrics"},{"issue":"21","key":"163_CR41","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1056\/NEJMoa0911781","volume":"362","author":"SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network","year":"2010","unstructured":"SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network (2010) Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 362(21):1959\u201369. https:\/\/doi.org\/10.1056\/NEJMoa0911781","journal-title":"N Engl J Med"},{"issue":"22","key":"163_CR42","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1056\/NEJMoa1302298","volume":"368","author":"The BOOST II United Kingdom, Australia, and New Zealand Collaborative Groups","year":"2013","unstructured":"The BOOST II United Kingdom, Australia, and New Zealand Collaborative Groups (2013) Oxygen saturation and outcomes in preterm infants. N Engl J Med 368(22):2094\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1302298","journal-title":"N Engl J Med"},{"issue":"20","key":"163_CR43","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1001\/jama.2013.5555","volume":"309","author":"B Schmidt","year":"2013","unstructured":"Schmidt B, Whyte RK, Asztalos EV, Moddemann D, Poets C, Rabi Y et al (2013) Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial. JAMA 309(20):2111. https:\/\/doi.org\/10.1001\/jama.2013.5555","journal-title":"JAMA"},{"key":"163_CR44","unstructured":"National Institute of Health and Care Excellence (2019) Specialist neonatal respiratory care for babies born preterm (NG124). Available from: www.nice.org.uk\/guidance\/ng124 [cited 28 June 2023]"},{"issue":"12","key":"163_CR45","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1684. https:\/\/doi.org\/10.1001\/archopht.121.12.1684","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"163_CR46","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3980\/j.issn.2222-3959.2013.02.23","volume":"6","author":"FM Mutlu","year":"2013","unstructured":"Mutlu FM, Sarici SU (2013) Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol 6(2):228\u2013236. https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2013.02.23","journal-title":"Int J Ophthalmol"},{"issue":"2","key":"163_CR47","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15(2):171\u2013185. https:\/\/doi.org\/10.1007\/s10456-011-9249-6","journal-title":"Angiogenesis"},{"issue":"7","key":"163_CR48","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.ophtha.2015.03.017","volume":"122","author":"S Mahmood","year":"2015","unstructured":"Mahmood S, Roberts SA, Aslam TM, Parkes J, Barugh K, Bishop PN et al (2015) Routine versus as-needed bevacizumab with 12-weekly assessment intervals for neovascular age-related macular degeneration: 92-week results of the GMAN trial. Ophthalmology 122(7):1348\u20131355. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.017","journal-title":"Ophthalmology"},{"issue":"20","key":"163_CR49","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1001\/jama.2017.4568","volume":"317","author":"IU Scott","year":"2017","unstructured":"Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC et al (2017) Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA 317(20):2072. https:\/\/doi.org\/10.1001\/jama.2017.4568","journal-title":"JAMA"},{"issue":"9","key":"163_CR50","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/17512433.2018.1507735","volume":"11","author":"S Sangroongruangsri","year":"2018","unstructured":"Sangroongruangsri S, Ratanapakorn T, Wu O, Anothaisintawee T, Chaikledkaew U (2018) Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol 11(9):903\u2013916. https:\/\/doi.org\/10.1080\/17512433.2018.1507735","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"163_CR51","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa2204225","volume":"387","author":"CD Jhaveri","year":"2022","unstructured":"Jhaveri CD, Glassman AR, Ferris FL, Liu D, Maguire MG, Allen JB et al (2022) Aflibercept monotherapy or bevacizumab first for diabetic macular edema. N Engl J Med 387(8):692\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa2204225","journal-title":"N Engl J Med"},{"issue":"7","key":"163_CR52","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603\u2013615. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"issue":"7","key":"163_CR53","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","volume":"118","author":"DM Moshfeghi","year":"2011","unstructured":"Moshfeghi DM, Berrocal AM (2011) Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology 118(7):1227\u20131228. https:\/\/doi.org\/10.1016\/j.ophtha.2011.04.028","journal-title":"Ophthalmology"},{"issue":"1","key":"163_CR54","first-page":"CD009734","volume":"2018","author":"MJ Sankar","year":"2018","unstructured":"Sankar MJ, Sankar J, Chandra P (2018) Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 2018(1):CD009734 Available from: http:\/\/doi.wiley.com\/10.1002\/14651858.CD009734.pub3 Cochrane Neonatal Group, editor [cited 21 June 2023]","journal-title":"Cochrane Database Syst Rev"},{"key":"163_CR55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.preteyeres.2017.09.002","volume":"62","author":"T Chan-Ling","year":"2018","unstructured":"Chan-Ling T, Gole GA, Quinn GE, Adamson SJ, Darlow BA (2018) Pathophysiology, screening and treatment of ROP: a multi-disciplinary perspective. Prog Retin Eye Res 62:77\u2013119. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.09.002","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"163_CR56","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C et al (2012) Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153(2):327\u2013333.e1. https:\/\/doi.org\/10.1016\/j.ajo.2011.07.005","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"163_CR57","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1167\/iovs.09-4140","volume":"51","author":"T Miyake","year":"2010","unstructured":"Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K et al (2010) Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in Macaque eyes. Investig Opthalmology Vis Sci 51(3):1606. https:\/\/doi.org\/10.1167\/iovs.09-4140","journal-title":"Investig Opthalmology Vis Sci"},{"issue":"1","key":"163_CR58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.joco.2018.10.008","volume":"31","author":"R Roohipoor","year":"2019","unstructured":"Roohipoor R, Torabi H, Karkhaneh R, Riazi-Eafahani M (2019) Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity. J Curr Ophthalmol 31(1):61\u201365. https:\/\/doi.org\/10.1016\/j.joco.2018.10.008","journal-title":"J Curr Ophthalmol"},{"issue":"2","key":"163_CR59","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/bjophthalmol-2017-310408","volume":"102","author":"RJ Hillier","year":"2018","unstructured":"Hillier RJ, Connor AJ, Shafiq AE (2018) Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series. Br J Ophthalmol 102(2):260\u2013264. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310408","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"163_CR60","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","volume":"138","author":"DK Wallace","year":"2020","unstructured":"Wallace DK, Kraker RT, Freedman SF, Crouch ER, Bhatt AR, Hartnett ME et al (2020) Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity. JAMA Ophthalmol 138(6):698. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.0334","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"163_CR61","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.ophtha.2022.05.019","volume":"129","author":"SF Freedman","year":"2022","unstructured":"Freedman SF, Hercinovic A, Wallace DK, Kraker RT, Li Z, Bhatt AR et al (2022) Low- and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes. Ophthalmology 129(10):1120\u20131128. https:\/\/doi.org\/10.1016\/j.ophtha.2022.05.019","journal-title":"Ophthalmology"},{"key":"163_CR62","unstructured":"NHS England Clinical Commissioning Policy (2023) Ranibizumab in retinopathy of prematurity (2201) [230401P]. Available from: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2023\/05\/2201-ranibizumab-in-retinopathy-of-prematurity-policy.pdf [cited 9 Aug 2023]"},{"key":"163_CR63","unstructured":"European Medicines Agency (2023) Lucentis: EPAR - product information. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lucentis-epar-product-information_en.pdf [cited 9 Aug 2023]"},{"issue":"10208","key":"163_CR64","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF et al (2019) Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 394(10208):1551\u20131559. https:\/\/doi.org\/10.1016\/S0140-6736(19)31344-3","journal-title":"Lancet"},{"issue":"4","key":"163_CR65","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","volume":"37","author":"WC Wu","year":"2017","unstructured":"Wu WC, Shih CP, Lien R, Wang NK, Chen YP, Chao AN et al (2017) Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina 37(4):694\u2013701. https:\/\/doi.org\/10.1097\/IAE.0000000000001209","journal-title":"Retina"},{"issue":"8","key":"163_CR66","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1167\/tvst.9.8.43","volume":"9","author":"M Fidler","year":"2020","unstructured":"Fidler M, Fleck BW, Stahl A, Marlow N, Chastain JE, Li J et al (2020) Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial. Transl Vis Sci Technol 9(8):43. https:\/\/doi.org\/10.1167\/tvst.9.8.43","journal-title":"Transl Vis Sci Technol"},{"key":"163_CR67","doi-asserted-by":"crossref","unstructured":"Stahl A, Br\u00fcnder M, Lagr\u00e8ze WA, Moln\u00e1r FE, Barth T, Eter N, et al (2022) Ranibizumab in retinopathy of prematurity \u2013 one\u2010year follow\u2010up of ophthalmic outcomes and two\u2010year follow\u2010up of neurodevelopmental outcomes from the CARE\u2010ROP study. Acta Ophthalmol 100(1)e91-e99. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.14852 [cited 21 June 2023]","DOI":"10.1111\/aos.14852"},{"issue":"3","key":"163_CR68","first-page":"1016","volume":"1","author":"YR Sharma","year":"2014","unstructured":"Sharma YR, Tripathy K, Venkatesh P, Gogia V (2014) Aflibercept \u2013 how does it compare with other anti-VEGF drugs? Austin J Clin Ophthalmol 1(3):1016","journal-title":"Austin J Clin Ophthalmol"},{"key":"163_CR69","unstructured":"Regeneron Pharmaceuticals, Inc (2023) EYLEA\u00ae (AFLIBERCEPT) Injection approved as the first pharmacologic treatment for preterm infants with Retinopathy of Prematurity (ROP) by the FDA. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/eylear-aflibercept-injection-approved-first-pharmacologic [cited 9 Aug 2023]"},{"key":"163_CR70","unstructured":"European Medicines Agency (2023) Eylea: EPAR - product information. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf"},{"issue":"4","key":"163_CR71","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jama.2022.10564","volume":"328","author":"A Stahl","year":"2022","unstructured":"Stahl A, Sukgen EA, Wu WC, Lepore D, Nakanishi H, Mazela J et al (2022) Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial. JAMA 328(4):348. https:\/\/doi.org\/10.1001\/jama.2022.10564","journal-title":"JAMA"},{"issue":"7","key":"163_CR72","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","volume":"6","author":"BW Fleck","year":"2022","unstructured":"Fleck BW, Reynolds JD, Zhu Q, Lepore D, Marlow N, Stahl A et al (2022) Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the RAINBOW trial. Ophthalmol Retina 6(7):628\u2013637. https:\/\/doi.org\/10.1016\/j.oret.2022.02.006","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"163_CR73","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3928\/23258160-20160229-12","volume":"47","author":"LL Snyder","year":"2016","unstructured":"Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP (2016) Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina 47(3):280\u2013283. https:\/\/doi.org\/10.3928\/23258160-20160229-12","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"12","key":"163_CR74","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","volume":"129","author":"E Chang","year":"2022","unstructured":"Chang E, Josan AS, Purohit R, Patel CK, Xue K (2022) A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity. Ophthalmology 129(12):1389\u20131401. https:\/\/doi.org\/10.1016\/j.ophtha.2022.06.042","journal-title":"Ophthalmology"},{"issue":"11","key":"163_CR75","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","volume":"41","author":"C Iwahashi","year":"2021","unstructured":"Iwahashi C, Utamura S, Kuniyoshi K, Sugioka K, Konishi Y, Wada N et al (2021) Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity. Retina 41(11):2261\u20132268. https:\/\/doi.org\/10.1097\/IAE.0000000000003196","journal-title":"Retina"},{"issue":"6","key":"163_CR76","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.oret.2019.12.015","volume":"4","author":"AE Hamad","year":"2020","unstructured":"Hamad AE, Moinuddin O, Blair MP, Schechet SA, Shapiro MJ, Quiram PA et al (2020) Late-onset retinal findings and complications in untreated retinopathy of prematurity. Ophthalmol Retina 4(6):602\u2013612. https:\/\/doi.org\/10.1016\/j.oret.2019.12.015","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"163_CR77","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","volume":"125","author":"D Lepore","year":"2018","unstructured":"Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH et al (2018) Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 125(2):218\u2013226. https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.005","journal-title":"Ophthalmology"},{"issue":"4","key":"163_CR78","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1542\/peds.2008-2697","volume":"123","author":"A Hellstr\u00f6m","year":"2009","unstructured":"Hellstr\u00f6m A, H\u00e5rd AL, Engstr\u00f6m E, Niklasson A, Andersson E, Smith L et al (2009) Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics 123(4):e638\u2013645. https:\/\/doi.org\/10.1542\/peds.2008-2697","journal-title":"Pediatrics"},{"issue":"9","key":"163_CR79","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jamaophthalmol.2018.2753","volume":"136","author":"G Binenbaum","year":"2018","unstructured":"Binenbaum G, Bell EF, Donohue P, Quinn G, Shaffer J, Tomlinson LA et al (2018) Development of modified screening criteria for retinopathy of prematurity: primary results from the postnatal growth and retinopathy of prematurity study. JAMA Ophthalmol 136(9):1034. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.2753","journal-title":"JAMA Ophthalmol"},{"key":"163_CR80","doi-asserted-by":"publisher","unstructured":"Moorthy S, Adams GGW, Smith G, Biswas S, Aliyan W, Bhudia R, et al (2023) Validation of the East London retinopathy of prematurity algorithm to detect treatment-warranted retinopathy of prematurity: a cohort study. Br J Ophthalmol bjo-2022-322522. https:\/\/doi.org\/10.1136\/bjo-2022-322522","DOI":"10.1136\/bjo-2022-322522"},{"issue":"12","key":"163_CR81","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1038\/s41433-022-02366-y","volume":"37","author":"A Ramanathan","year":"2023","unstructured":"Ramanathan A, Athikarisamy SE, Lam GC (2023) Artificial intelligence for the diagnosis of retinopathy of prematurity: a systematic review of current algorithms. Eye Lond Engl 37(12):2518\u20132526. https:\/\/doi.org\/10.1038\/s41433-022-02366-y","journal-title":"Eye Lond Engl"},{"key":"163_CR82","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fped.2019.00180","volume":"7","author":"L Filippi","year":"2019","unstructured":"Filippi L, Cavallaro G, Berti E, Padrini L, Araimo G, Regiroli G et al (2019) Propranolol 0.2% eye micro-drops for retinopathy of prematurity: a prospective phase IIB study. Front Pediatr 7:180. https:\/\/doi.org\/10.3389\/fped.2019.00180","journal-title":"Front Pediatr"}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-023-00163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40348-023-00163-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-023-00163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T18:29:05Z","timestamp":1700332145000},"score":1,"resource":{"primary":{"URL":"https:\/\/molcellped.springeropen.com\/articles\/10.1186\/s40348-023-00163-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["163"],"URL":"https:\/\/doi.org\/10.1186\/s40348-023-00163-5","relation":{},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"24 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review of existing literature did not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}